drugset / Trial / NCT05045781

Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects

NCT05045781

Phase 1 Completed 20 enrolled H. Lundbeck A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate how the body absorbs and get rid of eptinezumab when given directly into a vein in Chinese subjects.

Timeline

Start
2021-04-20
Primary completion
2021-07-20
Completion
2021-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptinezumab Monoclonal antibody 100 mg Intravenous
Subject Eptinezumab Monoclonal antibody 300 mg Intravenous

Indications

No indication recorded.